Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal bevacizumab for recurrent malignant ascites
ACTRN12624000288527Phase 3Recruiting
- Sponsor
- The University of Sydney
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab-bvzr in malignant ascites (2 arms), sponsored by The University of Sydney. Primary endpoint: Post-treatment Paracentesis Free Survival Time. Started Dec 2024; status: recruiting.
02
Drugs
bevacizumab-bvzr
03
Conditions
malignant ascites
Beyond the preview
Go deeper on ACTRN12624000288527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000288527.